

Respiratory syncytial virus: diagnosis, prevention and management

Rachael Barr, Christopher A. Green, Charles J. Sande and Simon B. Drysdale 

Ther Adv Infectious Dis

2019, Vol. 6: 1–9

DOI: 10.1177/
2049936119865798

© The Author(s), 2019.
Article reuse guidelines:
[sagepub.com/journals-](http://sagepub.com/journals-permissions)
permissions

Abstract: Respiratory syncytial virus (RSV) is responsible for a large burden of disease globally and can present as a variety of clinical syndromes in children of all ages. Bronchiolitis in infants under 1 year of age is the most common clinical presentation hospitalizing 24.2 per 1000 infants each year in the United Kingdom. RSV has been shown to account for 22% of all episodes of acute lower respiratory tract infection in children globally. RSV hospitalization, that is, RSV severe disease, has also been associated with subsequent chronic respiratory morbidity. Routine viral testing in all children is not currently recommended by the United Kingdom National Institute for Health and Care Excellence (NICE) or the American Academy of Pediatrics (AAP) guidance and management is largely supportive. There is some evidence for the use of ribavirin in severely immunocompromised children. Emphasis is placed on prevention of RSV infection through infection control measures both in hospital and in the community, and the use of the RSV-specific monoclonal antibody, palivizumab, for certain high-risk groups of infants. New RSV antivirals and vaccines are currently in development. Ongoing work is needed to improve the prevention of RSV infection, not only because of the acute morbidity and mortality, but also to reduce the associated chronic respiratory morbidity after severe infection.

Keywords: cohorting, infection control, nosocomial infection, palivizumab, respiratory syncytial virus, RSV

Received: 11 February 2019; revised manuscript accepted: 3 July 2019.

Introduction

Respiratory syncytial virus (RSV) is a ubiquitous pathogen infecting almost all children by 2 years of age.¹ RSV infection can present as a variety of clinical syndromes including upper respiratory tract infections (URTIs), bronchiolitis, pneumonia, exacerbations of asthma and viral-induced wheeze. The greatest burden of severe disease needing hospitalization is in infants under 1 year of age.¹ It was estimated that globally in 2015 there were 33.1 million episodes of RSV acute lower respiratory tract infection (ALRI), 3.2 million hospital admissions and 59,600 in-hospital deaths in children under 5 years of age.² Data combining both hospital and community deaths estimated 94,600–149,400 global deaths annually.² A Canadian study investigating factors associated with

RSV-related mortality in children found that the median age of death was 11 months and healthcare associated infections accounted for 36.7% of deaths. Although the majority of the deaths in this study were in children with chronic medical conditions or underlying immunocompromise, one in five deaths occurred in children with no known risk factors for severe clinical disease.³ Globally RSV is the most common cause of lower respiratory tract infections in childhood, accounting for 22% of all episodes of ALRI.^{1,4}

In the United Kingdom (UK), RSV accounts for an average of 29,160 hospital admissions and 83 deaths per RSV season (October to March).⁵ Furthermore, of the infants requiring hospital admission with RSV infection in the first year of

Correspondence to:

Simon B. Drysdale
Institute for Infection and
Immunity, St George's,
University of London,
Cranmer Terrace,
London, SW17 0RE, UK

Oxford Vaccine Group,
Department of Paediatrics,
University of Oxford, OX3
9DU, UK

NIHR Oxford Biomedical
Research Centre, Level 2,
Children's Hospital, Oxford
OX3 9DU, UK

simon.drysdale@nhs.net

Rachael Barr
Musgrove Park Hospital,
Taunton and Somerset
NHS Foundation Trust,
Taunton, UK

Christopher A. Green
Charles J. Sande
Oxford Vaccine Group,
Department of Paediatrics,
University of Oxford, UK

life, 2–6% of them will require management in a paediatric intensive care unit.⁶ The impact extends beyond the hospital setting into the community, with an estimated 450,000 general practitioner (GP) episodes for children and adolescents annually.⁵ Although the greatest burden is in infants less than 6 months old, followed by those 6–23 months old, 36% of those GP consultations were in the 2–4 year-old age group.⁵

Healthcare costs associated with RSV infection in children younger than 5 years of age have been estimated at £50–57 million annually in the UK with approximately £37 million of this attributable to those children requiring hospitalization. The costs of hospitalization are roughly evenly split between infants less than 6 months old and those 6 months–5 years old.⁷ Annual costs related to GP consultations are estimated at £16–19 million.⁷

RSV bronchiolitis

Bronchiolitis is an inflammatory process in the small airways of the lungs and is the most common clinical syndrome associated with RSV infection. It typically presents in infants under 1 year of age but may be diagnosed in children up to 2 years old, and is characterized by a short history of low-grade fever, cough, coryza, difficulty in breathing and reduced feeding. The symptoms usually peak in clinical severity between day 3 and 5 of illness.⁸ It is important to remain vigilant to the fact that very young infants (under 6 weeks of age) may present with apnoea alone in the absence of other clinical signs or symptoms.⁸

There are a number of risk factors that predispose infants to developing RSV infection within a given season including the presence of an older sibling, birth proximity to the RSV season, low birth weight, male sex, young age (<6 months), exposure to smoking, young maternal age and suburban residence.¹ Risk factors for more severe disease include premature birth, congenital heart disease, chronic lung disease and immunodeficiency.⁸ Cystic fibrosis, Down syndrome, cerebral palsy and timing of birth in close proximity to the RSV season, that is, birth in September and October, are also associated with a higher risk of requiring hospital admission for RSV infection.⁹ However, 85% of infants admitted to hospital with RSV bronchiolitis are born at term without any known risk factors for severe disease.⁹

RSV bronchiolitis presents a significant clinical burden with hospital admissions in the UK of 24.2 per 1000 infants.⁹ Rates are similar in the United States (US) where between 1997 and 2006 the rate of RSV associated hospitalization in children under one year of age was 26.0 per 1000 infants.¹⁰ In the UK, infection with RSV is responsible for up to 80% of all cases of bronchiolitis, similar to that of 65–70% in the US.^{6,11}

RSV infection in older children

In older children, RSV typically presents as an URTI, viral pneumonia, episodic viral-induced wheeze or an acute exacerbation of asthma. Viral pneumonia is a common illness with 5 million cases reported in children in developed countries annually.¹² A meta-analysis of nine studies involving over 4000 children investigating viruses identified by polymerase chain reaction, found that RSV was the causative organism in 11% of community-acquired pneumonia cases.¹²

Viral-induced or episodic wheeze is the clinical syndrome of wheezing associated with periods of clinically evident viral infection with no interval symptoms. It most commonly presents in preschool-aged children and RSV is among the most common causative agent with one study finding it in 33% of symptomatic children.^{13,14} Episodic viral wheeze is a very common clinical syndrome with one study across the US and six European countries showing that 42% of preschool children reported recurrent days of wheeze in the preceding 6 months over winter.¹⁵ Some children included in this study may have been exhibiting the initial symptoms of asthma rather than episodic wheeze. Atopic asthma is a clinically distinct syndrome in which symptoms tend to be persistent and may have multiple triggers. RSV is associated with acute exacerbations of asthma in school-aged children; however, unlike in younger children, RSV plays a relatively minor role in this cohort, with rhinovirus being the most significant contributory pathogen (rhinovirus 50–60% *versus* RSV 1.5%).^{16,17}

Clinical usefulness of respiratory virus testing

Respiratory viral testing may be used in a clinical setting to increase confidence in the diagnosis of a viral, rather than bacterial, cause for respiratory illness.^{18,19} Given the typically short duration of the clinical illness, a rapid diagnostic test is required in

order to have an impact on clinical decision-making. A meta-analysis of RSV rapid diagnostic tests found that summary sensitivities and specificities for these tests were 75.3% and 98.7% respectively.²⁰ This suggests that although false negatives are not uncommon, a positive result may increase confidence in the diagnosis and could support decision-making, such as reducing the likelihood of prescribing an antibiotic inappropriately. A number of studies have demonstrated that the use of point-of-care respiratory virus testing reduces the number of prescriptions for, and duration of, antibiotic treatment as well as reducing investigations such as blood tests, urinalysis and chest X-rays.^{18,21–24} Studies investigating the use of respiratory viral testing in the emergency department (ED) have also demonstrated a reduction in the length of time spent in the ED by an average of 40 min.^{22,23} Clinicians, however, need to maintain an awareness of the possibility of concomitant viral and bacterial infection. One study highlighted that two patients (1.2%) who had tested positive for a respiratory virus also had a culture-proven bacterial infection.²¹

The National Institute for Health and Care Excellence (NICE) guidelines and American Academy of Pediatrics (AAP) guidelines for bronchiolitis do not recommend respiratory viral testing routinely in children in whom bronchiolitis is clinically suspected.^{8,11} The AAP guideline comments that the benefit to the individual patient of respiratory viral testing has not been established and only recommends testing in the specific event that a child receiving monthly palivizumab injections has been admitted with bronchiolitis. In this circumstance, a positive result could mean that further doses of palivizumab would not be needed.¹¹ Respiratory virus testing may be considered in other circumstances and has previously been reviewed in detail.¹⁹ A national survey looking at management practices of bronchiolitis across the UK found that routine testing of hospitalized infants for respiratory viruses dropped from 72% prior to the NICE guideline publication to 44% after.²⁵

Investigations and treatment for RSV infection

As discussed above, respiratory viral testing may be of some benefit in the investigation of children with symptoms suggestive of RSV infection. However, further investigation including blood

tests or chest X-rays are not currently routinely recommended in children with bronchiolitis or episodic viral wheeze.^{8,26} A chest X-ray may be considered in children in whom intensive care is being proposed or those with atypical disease, and blood gas measurement if there is severe worsening respiratory distress or suspected impending respiratory failure.^{8,26}

Treatment of RSV infection remains supportive (oxygen supplementation and feeding support) in most clinical scenarios. In infants with bronchiolitis there is no evidence of benefit for bronchodilators, corticosteroids, antibiotics, nebulized epinephrine, leukotriene inhibitors, nebulized hypertonic saline or chest physiotherapy.^{27–33} Ribavirin is licensed for use as a treatment for infants with bronchiolitis. However, the most recent Cochrane review of its use in 2007 suggested that the available evidence at that time was insufficient to confidently state whether or not ribavirin is clinically effective at treating RSV bronchiolitis.³⁴ Therefore, due to its side-effect profile and lack of reproducible data on efficacy it is not currently recommended for routine use in RSV bronchiolitis in infants in the UK or US. The inhaled form of the drug is also extremely costly with wholesale prices for a single day of treatment quoted at US\$29,000 in the US.³⁵

There is limited evidence for use of ribavirin in certain high-risk groups of children, such as those who have undergone a haemopoietic stem cell transplant (HSCT) or those who are severely immunocompromised. One small study looking at 28 patients who had undergone HSCT, 24 of whom received ribavirin showed a reduction in mortality in those receiving ribavirin with a risk ratio of 0.33 [95% confidence interval (CI) 0.17–0.64, $p=0.001$].³⁶ A review of studies reporting a total of 273 cases of RSV infection in HSCT patients found 44 patients with an URTI were treated with ribavirin, of which 25% progressed to a lower respiratory tract infection (LRTI) in comparison with 47% of those who did not receive ribavirin ($p=0.01$).³⁷ Of 128 patients with a LRTI, 50% treated with ribavirin died compared with 89% not treated ($p=0.04$).³⁷ Although these results suggest a role for ribavirin in this population the included studies had small numbers of patients and different study designs and cannot be easily used to produce a single summary statistic.

Another treatment that has been considered in the treatment of RSV is intravenous immunoglobulin (IVIG), either standard or RSV-specific. A Cochrane review looking at four studies using immunoglobulin therapy found that although it may be effective at lowering viral titres, it did not appear to correlate with improved clinical outcomes.³⁸ However, of the four studies included, one looked at intravenous human normal immunoglobulin (IVIG), two at RSV-specific immunoglobulin and one at aerosolized immunoglobulin. Overall, two studies were performed on otherwise healthy children with RSV infection and two on children with risk factors for severe disease. RSV-specific immunoglobulin was removed from the market in 2004 and is no longer available. Palivizumab, a humanized mouse monoclonal antibody, is an effective prophylactic agent against RSV but has also been trialled as an RSV treatment. However, even among immunocompromised patients it has not been shown to reduce mortality or progression to LRTIs when used as a treatment.^{39,40}

Ribavirin and immunoglobulin given together has also been investigated as a therapeutic option. A review of 13 studies in adults who had undergone HSCT showed a reduced risk of progression from URTI to LRTI (12% *versus* 25%, $p=0.13$) and reduced RSV-specific mortality (24% *versus* 50%, $p<0.001$) in patients who received dual therapy when compared with those using ribavirin alone.⁴¹ The British Society for Haematology currently recommends that adult patients who have undergone an allogeneic stem cell transplant and who have risk factors for progression of RSV URTI to LRTI should receive aerosolized or oral ribavirin in combination with IVIG.⁴² We are not aware of any similar paediatric data or guidance.

In older children with episodic viral wheeze or an exacerbation of asthma, inhaled bronchodilators are recommended, along with a short course of oral corticosteroids in children with asthma or those with episodic wheeze and a clear history of atopy.^{26,43} There is no role for antiviral treatment in this clinical scenario.

Transmission of RSV and preventing nosocomial infections in hospital

RSV is a human restricted pathogen and typically spreads *via* hands, fomites and the aerosol route.⁴⁴

The basic reproduction number (R_0 , the number of cases one case generates on average over the course of its infectious period, in an otherwise uninfected population) of RSV is estimated to be between 1.2 and 3.0 (similar to that of influenza).^{45,46} This knowledge is important for preventing RSV transmission, both in the community and in the hospital setting. Within families, RSV has been shown to spread rapidly with one study investigating 52 families with a child hospitalized for RSV infection finding that in 77% of families at least one other member was RSV-positive.⁴⁷ Furthermore, in 58% of cases, a parent or older sibling was considered to be the likely primary case within the family highlighting the importance of preventing transmission where possible.⁴⁷

Within the hospital setting, the NICE guideline on bronchiolitis does not give advice on cohorting infants or infection prevention and control procedures to prevent nosocomial spread.⁸ A national survey in the UK found that individual trusts use a variety of cohorting practices including cohorting infants with the same causative virus, cohorting those with RSV, cohorting all infants with a clinical diagnosis of bronchiolitis in cubicles and cohorting all infants with a clinical diagnosis of bronchiolitis together, regardless of the causative virus.²⁵ These practices did not change significantly with the publication of the NICE guidance in 2015.²⁵ The AAP guideline recommends decontamination of hands with alcohol-based gel before and after every patient contact when managing patients with RSV.¹¹ A systematic review of infection control measures to prevent nosocomial RSV transmission found that multicomponent interventions appeared to be most effective, with reductions in transmission of up to 50%.⁴⁸ The interventions studied included case-finding, screening on admission, patient and staff cohorting, restriction of visitors, staff training and use of personal protective equipment.⁴⁸ Prevention of nosocomial transmission of RSV is particularly important as it has been demonstrated that infants with nosocomial infection have a more severe clinical course compared with those with community-acquired disease.⁴⁹ Some studies have suggested that infants with nosocomial infection may have a higher mortality rate (0–12.2% higher) than those with community-acquired infection.⁵⁰ A study in Canada looking at mortality from RSV infections found that 36.7% of deaths from RSV were attributable to nosocomially acquired infection.³ Given

that these infants tend to have a more severe clinical course, the associated cost of nosocomial infections is higher. A study in the US compared costs between children with nosocomial and community-acquired RSV infection. They found that the mean cost per patient was between US\$20,347 and US\$45,335 higher in nosocomial infections than in community-acquired infections.⁵¹

Preventing severe RSV infection

A number of independent risk factors have been shown to be associated with RSV hospitalization as highlighted above. Some of these risk factors are modifiable, for example, parents should be encouraged not to smoke. For certain groups of infants at high risk of severe RSV infection palivizumab, a monoclonal antibody directed against an antigenic site in the RSV fusion (F) protein, is recommended as a preventive measure.⁵² Palivizumab is currently recommended for use in the UK in the following groups of children:⁵²

- Preterm infants who have moderate or severe bronchopulmonary dysplasia (BPD) at specific chronological ages at the start of the RSV season.
- Infants with respiratory diseases (e.g. pulmonary hypoplasia due to congenital diaphragmatic hernia and interstitial lung disease) requiring oxygen or long-term ventilation at the start of the RSV season.
- Preterm infants with haemodynamically significant acyanotic congenital heart disease.
- Children with cyanotic or acyanotic congenital heart disease with significant comorbidity.
- Children under 24 months with severe combined immunodeficiency (SCID).⁵²

Palivizumab is given as an intramuscular injection monthly (up to five doses) during the RSV season.⁵² Although it is currently licensed for use in the above groups of children, its high cost of £3000–£5000 per patient per season has meant that there have been ongoing cost-effectiveness controversies. It may only be cost effective in the subgroups of infants at the highest risk of severe disease.^{53–55} A systematic review and subgroup analysis has suggested that at a willingness-to-pay threshold of £30,000 per quality-adjusted life

year, the subgroups in which palivizumab is cost-effective may be much more restrictive.⁵⁴ For example, one subgroup in which palivizumab was found to be cost-effective was those with congenital cyanotic heart disease who are less than 6 weeks old at the start of the RSV season and were born at less than 25 weeks of gestational age.⁵⁴ Palivizumab currently remains the only preventive medication licensed for use in the UK or US.

Chronic respiratory morbidity after RSV infection in infancy

Severe RSV bronchiolitis in the first year of life is associated with an increased risk of wheeze and asthma in later life.^{56–58} A study investigating infants with mild RSV infection in the first year of life not requiring hospitalization showed that RSV was associated with an increased risk of wheezing at 1 year of age (OR = 1.6).⁵⁹ It has been debated whether early-life RSV infection causes damage to the lungs resulting in a predisposition to wheeze later in life, or whether these infants already have a subclinical underlying problem with their lung function that predisposes them to both severe RSV infection and later-life wheezing.⁶⁰ A causal relationship between early RSV infection and later wheezing is supported by data suggesting prophylactic palivizumab reduces recurrent wheezing episodes in infants born prematurely.^{61,62} One study found that in infants born at less than 35 weeks of gestation, the incidence of recurrent wheezing in those who received palivizumab was 13% *versus* 26% in those who did not ($p = 0.001$), giving a risk ratio of 0.51 (95% CI 0.33–0.78).⁶¹ A second placebo-controlled, double blind study of infants born at 33–35 weeks of gestation found a relative reduction in total number of wheezing days in the first year of life of 61% in infants who received palivizumab *versus* those who received placebo (95% CI 56–65%).⁶² It has been debated whether these effects, if true, are long lasting and follow up of the infants in the study by Blanken and colleagues at 6 years of age showed a reduction in parental-reported asthma but no difference in the proportion of children with physician-diagnosed current asthma or lung function between those who received palivizumab or placebo.⁶³ Another 6-year follow-up study of children administered with palivizumab during their first RSV season, showed a reduction in physician-diagnosed recurrent wheeze over the study period (15.3% in those who received

palivizumab *versus* 31.6% in those who did not, $p=0.003$).⁶⁴ However, it did not show a significant difference in the prevalence of atopic asthma at 6 years of age between the two groups (15.3% *versus* 18.2%, $p=0.57$).⁶⁴

In contrast with this and not supportive of a causative link between severe RSV infection and subsequent chronic respiratory morbidity, term-born infants receiving another similar F-specific monoclonal antibody against RSV, motavizumab, did not show a difference compared with placebo in the presence of wheeze when followed up to 3 years of age.⁶⁵ These differences may be due to inherent differences in the lungs or immunity of prematurely and term-born infants. It is thus still not clear what role severe RSV infection in infancy plays in the development of chronic respiratory morbidity.

Future horizons in RSV vaccines and other anti-RSV therapeutics

Given the huge burden of disease and the associated costs caused by RSV globally there is much ongoing research into the development of a well-tolerated and effective vaccine. The main target populations for vaccination include infants, school age children, pregnant women and older adults. Multiple different vaccine approaches are being considered including live-attenuated/chimeric, whole-inactivated, particle-base, subunit, nucleic acid and gene-based vectors. There are also ongoing efforts to develop long acting (to cover a whole RSV season) monoclonal antibodies (mAbs) for infants. These vaccines and mAbs have recently been reviewed by Mazur and colleagues.⁶⁶ A phase III clinical trial (ClinicalTrials.gov identifier: NCT02624947) of an RSV maternal vaccine has recently completed. Unfortunately, it did not reach its primary endpoint of prevention of medically significant RSV LRTI but did show vaccine efficacy of 44% against RSV LRTI hospitalizations and 48% against RSV LRTI with severe hypoxaemia.⁶⁷ It is likely that a licensed RSV vaccine is several years away at least. In addition, three agents have been extensively used and investigated as antiviral treatments for RSV (namely ribavirin, IVIG and palivizumab). None have proven to be an unequivocally beneficial and effective treatment and so research continues into future therapies. There are at least 14 anti-RSV treatment products undergoing clinical trials (phase I and II only), of which 5 have so far included paediatric patients.⁶⁸

Types of novel therapeutic molecules that have been developed include fusion inhibitors, nonfusion inhibitors, polymerase inhibitors, antibodies, nucleoside analogues, small-interfering RNAs and a benzodiazepine. They have various targets on RSV such as the F protein, RNA polymerase, nucleoprotein and nucleocapsid mRNA.⁶⁸ Over the coming years it is hoped one of these products will become a licensed treatment for RSV infection in children (and adults).

Summary

RSV is a ubiquitous infection with a significant global clinical and financial burden. Currently the management of RSV in infants and children is primarily supportive with antiviral medications reserved for only the most vulnerable populations. Palivizumab continues to be the only effective prophylactic medication licensed for use; however, its high cost prevents it from being used in all infants. Given these factors, the development of a well-tolerated, clinically effective and cost-effective RSV vaccine and therapeutic agent remains a major unmet global health priority.

Author's Note

Rachael Barr is now affiliated to Bristol Children's Hospital, University Hospitals Bristol NHS Foundation Trust, BS2 8BJ

Funding

This work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre and the NIHR Thames Valley and South Midlands Clinical Research Network. SBD and CJS are members of the REspiratory Syncytial virus Consortium in EUrope (RESCEU). RESCEU has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (grant number 116019). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA (www.imi.europa.eu).

Conflict of interest statement

The authors declare that there is no conflict of interest.

ORCID iD

Simon B Drysdale  <https://orcid.org/0000-0002-6350-6557>

References

1. Bont L, Checchia PA, Fauroux B, *et al.* Defining the epidemiology and burden of severe respiratory syncytial virus infection among infants and children in western countries. *Infect Dis Ther* 2016; 5: 271–298.
2. Shi T, McAllister DA, O'Brien KL, *et al.* Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet* 2017; 390: 946–958.
3. Tam J, Papenburg J, Fanella S, *et al.* Pediatric investigators collaborative network on infections in Canada study of respiratory syncytial virus-associated deaths in pediatric patients in Canada, 2003–2013. *Clin Infect Dis* 2019; 68: 113–119.
4. Nair H, Nokes DJ, Gessner BD, *et al.* Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. *Lancet (London, England)* 2010; 375: 1545–1555.
5. Taylor S, Taylor RJ, Lustig RL, *et al.* Modelling estimates of the burden of respiratory syncytial virus infection in children in the UK. *BMJ Open* 2016; 6: e009337.
6. Green CA, Yeates D, Goldacre A, *et al.* Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. *Arch Dis Child* 2016; 101: 140–146.
7. Cromer D, van Hoek AJ, Newall AT, *et al.* Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. *Lancet Public Heal* 2017; 2: e367–e374.
8. Bronchiolitis in children: diagnosis and management and Guidance and guidelines and NICE.
9. Murray J, Bottle A, Sharland M, *et al.* Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. Schildgen O, editor. *PLoS One*. 2014; 9: e89186.
10. Stockman LJ, Curns AT, Anderson LJ, *et al.* Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997–2006. *Pediatr Infect Dis J* 2012; 31: 5–9.
11. Ralston SL, Lieberthal AS, Meissner HC, *et al.* Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. *Pediatrics* 2014; 134: e1474–e1502.
12. Ruuskanen O, Lahti E, Jennings LC, *et al.* Viral pneumonia. *Lancet* 2011; 377: 1264–1275.
13. Brand PLP, Baraldi E, Bisgaard H, *et al.* Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. *Eur Respir J* 2008; 32: 1096–1110.
14. Takeyama A, Hashimoto K, Sato M, *et al.* Clinical and epidemiologic factors related to subsequent wheezing after virus-induced lower respiratory tract infections in hospitalized pediatric patients younger than 3 years. *Eur J Pediatr* 2014; 173: 959–966.
15. Bisgaard H and Szefer S. Prevalence of asthma-like symptoms in young children. *Pediatr Pulmonol* 2007; 42: 723–728.
16. Khetsuriani N, Neely Kazerouni N, Erdman DD, *et al.* Prevalence of viral respiratory tract infections in children with asthma. *J Allergy Clin Immunol* 2007; 119: 314–321.
17. Busse WW, Lemanske RF, Gern JE, *et al.* Role of viral respiratory infections in asthma and asthma exacerbations. *Lancet (London, England)* 2010; 376: 826–834.
18. Rogan DT, Kochar MS, Yang S, *et al.* Impact of rapid molecular respiratory virus testing on real-time decision making in a pediatric emergency department. *J Mol Diagn* 2017; 19: 460–467.
19. Drysdale SB and Kelly DF. How to use. . .respiratory viral studies. *Arch Dis Child Educ Pract Ed* 2018; doi: 10.1136/archdischild-2016-311858.
20. Bruning AHL, Loefflang MMG, Vos JMBW, *et al.* Rapid tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review and meta-analysis. *Clin Infect Dis* 2017; 65: 1026–1032.
21. Byington CL, Castillo H, Gerber K, *et al.* The effect of rapid respiratory viral diagnostic testing on antibiotic use in a children's hospital. *Arch Pediatr Adolesc Med* 2002; 156: 1230.
22. Abanes JC, Dowd MD, Simon SD, *et al.* Impact of rapid influenza testing at triage on management of febrile infants and young children. *Pediatr Emerg Care* 2006; 22: 145–149.
23. Bonner AB, Monroe KW, Talley LI, *et al.* Impact of the rapid diagnosis of influenza on physician decision-making and patient management in the pediatric emergency department: results

- of a randomized, prospective, controlled trial. *Pediatrics* 2003; 112: 363–367.
24. Keske , Ergönül Ö, Tutucu F, *et al.* The rapid diagnosis of viral respiratory tract infections and its impact on antimicrobial stewardship programs. *Eur J Clin Microbiol Infect Dis* 2018; 37: 779–783.
 25. Barr R, Carande EJ, Pollard AJ, *et al.* Change in viral bronchiolitis management in hospitals in the UK after the publication of NICE guideline. *J Clin Virol* 2018; 105: 84–87.
 26. NICE. Cough - acute with chest signs in children, <https://cks.nice.org.uk/cough-acute-with-chest-signs-in-children#!scenario> (2017, accessed 9 December 2018).
 27. Gadomski AM and Scribani MB. Bronchodilators for bronchiolitis. In: Gadomski AM (ed.) *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2014.
 28. Fernandes RM, Bialy LM, Vandermeer B, *et al.* Glucocorticoids for acute viral bronchiolitis in infants and young children. In: Fernandes RM (ed.) *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2013.
 29. Farley R, Spurling GK, Eriksson L, *et al.* Antibiotics for bronchiolitis in children under two years of age. In: Spurling GK (ed.) *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2014.
 30. Hartling L, Bialy LM, Vandermeer B, *et al.* Epinephrine for bronchiolitis. In: Hartling L (ed.) *Cochrane database of systematic reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2011.
 31. Liu F, Ouyang J, Sharma AN, *et al.* Leukotriene inhibitors for bronchiolitis in infants and young children. In: Liu S (ed.) *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2015.
 32. Zhang L, Mendoza-Sassi RA, Wainwright C, *et al.* Nebulised hypertonic saline solution for acute bronchiolitis in infants. In: Zhang L (ed.) *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2013.
 33. Roqué i Figuls M, Giné-Garriga M, Granados Rugeles C, *et al.* Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. In: Vilaró J (ed.) *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2016.
 34. Ventre K and Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. In: Ventre K (ed.) *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2007.
 35. Chemaly RF, Aitken SL, Wolfe CR, *et al.* Aerosolized ribavirin: the most expensive drug for pneumonia. *Transpl Infect Dis* 2016; 18: 634–636.
 36. Waghmare A, Campbell AP, Xie H, *et al.* Respiratory syncytial virus lower respiratory disease in hematopoietic cell transplant recipients: viral RNA detection in blood, antiviral treatment, and clinical outcomes. *Clin Infect Dis* 2013; 57: 1731–1741.
 37. Hynicka L. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. *Ann Pharmacother* 2012; 46: 558–566.
 38. Fuller HL and Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. In: Fuller HL (ed.) *Cochrane database of systematic reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2006.
 39. de Fontbrune FS, Robin M, Porcher R, *et al.* Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. *Clin Infect Dis* 2007; 45: 1019–1024.
 40. Roberto PS, Jeffery C, Anne GN, *et al.* The use of intravenous palivizumab for treatment of persistent rsv infection in children with leukaemia. *Pediatrics* 2012; 130.
 41. Shah JN and Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. *Blood* 2011; 17: 2755–2763.
 42. Dignan FL, Clark A, Aitken C, *et al.* BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. *Br J Haematol* 2016; 173: 380–393.
 43. British Thoracic Society. British guideline on the management of asthma. *Quick Reference Guide*. 2016.
 44. Smith C, Hirst R, Baker N, *et al.* Airborne transmission of respiratory syncytial virus (RSV) infection. *Euro Res J* 2011; 38: 1722.
 45. Reis J and Shaman JL. Retrospective parameter estimation and forecast of respiratory syncytial virus in the United States. 2016; 12: 1–15.
 46. Weber A, Weber M and Milligan P. Modeling epidemics caused by respiratory syncytial virus (RSV). *Math Biosci* 2001; 172: 95–113.

47. Heikkinen T, Valkonen H, Waris M, *et al.* Transmission of respiratory syncytial virus infection within families. *Open Forum Infect Dis* 2015; 2: ofu118.
48. French CE, McKenzie BC, Coope C, *et al.* Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review. *Influenza Other Respir Viruses* 2016; 10: 268–290.
49. Simon A, Müller A, Khurana K, *et al.* Nosocomial infection: A risk factor for a complicated course in children with respiratory syncytial virus infection: results from a prospective multicenter German surveillance study. *Int J Hyg Environ Health* 2008; 211: 241–250.
50. Welliver RC, Checchia PA, Bauman JH, *et al.* Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. *Curr Med Res Opin* 2010; 26: 2175–2181.
51. Macartney KK, Gorelick MH, Manning ML, *et al.* Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control. *Pediatrics* 2000; 106: 520–526.
52. Public Health England. Chapter 27a: Respiratory Syncytial Virus. *Department of Health (2006) Immunisation against infectious disease (Green Book)*. 2015, London: Department of Health
53. Teale A, Deshpande S and Burls A. Palivizumab and the importance of cost effectiveness. *BMJ* 2009; 338: b1935.
54. Wang D, Bayliss S and Meads C. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: systematic review and additional economic modelling of subgroup analyses. *Health Technol Assess (Rockv)* 2011; 15.
55. Bentley A, Filipovic I, Gooch K, *et al.* A cost-effectiveness analysis of respiratory syncytial virus (RSV) prophylaxis in infants in the United Kingdom. *Health Econ Rev* 2013; 3: 18.
56. Sigurs N, Aljassim F, Kjellman B, *et al.* Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. *Thorax* 2010; 65: 1045–1052.
57. Sigurs N, Gustafsson PM, Bjarnason R, *et al.* Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. *Am J Respir Crit Care Med* 2005; 171: 137–141.
58. Stein RT, Sherrill D, Morgan WJ, *et al.* Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *Lancet* 1999; 354: 541–545.
59. Gebretsadik T, Anderson LJ, Jadhao S, *et al.* Risk or protective factor? mild respiratory syncytial virus infection in infancy and the development of recurrent childhood wheeze. *American Journal of Respiratory and Critical Care Medicine* 2017; 195: A5028.
60. Meissner HC. Viral Bronchiolitis in Children. *The New England Journal of Medicine* 2016; 374: 62–72. DOI: 10.1056/NEJMra1413456.
61. Simoes EAF, Groothuis JR, Carbonell-Estrany X, *et al.* Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. *J Pediatr* 2007; 151: 34–42.e1.
62. Blanken MO, Rovers MM, Molenaar JM, *et al.* Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. *N Engl J Med* 2013; 368: 1791–1799.
63. Scheltema NM, Nibbelke EE, Pouw J, *et al.* Respiratory syncytial virus prevention and asthma in healthy preterm infants: a randomised controlled trial. *Lancet Respir Med* 2018; 6: 257–264.
64. Mochizuki H, Kusuda S, Okada K, *et al.* Palivizumab prophylaxis in preterm infants and subsequent recurrent wheezing. Six-year follow-up study. *Am J Respir Crit Care Med* 2017; 196: 29–38.
65. O'Brien KL, Chandran A, Weatherholtz R, *et al.* Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. *Lancet Infect Dis* 2015; 15: 1398–1408.
66. Mazur NI, Higgins D, Nunes MC, *et al.* The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. *Lancet Infect Dis* 2018; 18: e295–e311.
67. Novavax Inc. Novavax announces topline results from phase 3 Prepare™ Trial of ResVax™ for prevention of rsv disease in infants via maternal immunization, <http://ir.novavax.com/news-releases/news-release-details/novavax-announces-topline-results-phase-3-preparetm-trial> (2019, accessed 5 March 2019).
68. Nicholson EG and Munoz FM. A review of therapeutics in clinical development for respiratory syncytial virus and influenza in children. *Clin Ther* 2018; 40: 1268–1281.